从全球血制品龙头CSL的2017中报看过去

Global biotechnology leader CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP). Reported earnings per share (EPS) grew 14%. Underlying2 NPAT grew 36% and earnings per share (EPS) increased 39% on a constant currency (CC)3 basis, after excluding the one-off items related to the Novartis influenza vaccines business acquisition during the previous period.

PERFORMANCE HIGHLIGHTS

Financial

· Revenue $3,677 million

· Up 18% at CC

· Earnings before interest and tax (EBIT) $1,095 million

· Underlying EBIT up 38% at CC

· NPAT $806 million

· Underlying NPAT up 36% at CC

· EPS $1.77

· Reported EPS up 14%

· Underlying EPS up 39% at CC

· Interim dividend4 increased to $0.64 per share

CSL半年报收入36.77亿美金，同比增长18%，EBIT为10.95亿美金，同比增长38%，税后利润8.06亿美金，同比增长36%，CSL的血液制品收入占总收入比率为9成，换算下，今天CSL收入接近70亿美金。而目前中国最大的血制品公司上海莱仕2016年收入才22.48亿人民币，还需要我多说什么吗？

再看看世界血制品的总收入在哪里？根据MRB预测，直接上图：

而如果算上重组产品，2015年重组凝血因子的销售额达到80亿美金，看懂了没？这个市场哪怕到了今天还在高速发展，而且随着适应症的不断增加，需求也呈现出高速增长的态势。

炒股得独立思考，有大格局和长远的眼光，不要被所谓V忽悠，很多V的水平真的很一般，当然营销水平都不错，

总结一句：中国的血制品行业还仅仅处于儿童阶段；对于行业中的龙头天坛生物而言，天空才是你的尽头！

$天坛生物(SH600161)$ $博雅生物(SZ300294)$ $华兰生物(SZ002007)$